The efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin in hepatitis C virus-infected patients with end-stage renal disease on regular hemodialysis
Background and aim Infection with hepatitis C virus (HCV) is an important cause of mortality and morbidity in patients with end-stage renal disease. Direct-acting antiviral drugs allow for the treatment of this group of patients. The current research aims to assess the efficacy and safety of ombitas...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
General Organization of Teaching Hospitals and Institutes
2021-01-01
|
| Series: | Journal of Medicine in Scientific Research |
| Subjects: | |
| Online Access: | http://www.jmsr.eg.net/article.asp?issn=2537-091X;year=2021;volume=4;issue=2;spage=170;epage=175;aulast=A. |
| _version_ | 1797227071313805312 |
|---|---|
| author | Muhammad M A. Ghaffar Dalia Omran Enass El Sayed |
| author_facet | Muhammad M A. Ghaffar Dalia Omran Enass El Sayed |
| author_sort | Muhammad M A. Ghaffar |
| collection | DOAJ |
| description | Background and aim
Infection with hepatitis C virus (HCV) is an important cause of mortality and morbidity in patients with end-stage renal disease. Direct-acting antiviral drugs allow for the treatment of this group of patients. The current research aims to assess the efficacy and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) combination therapy plus ribavirin in the treatment of HCV-infected Egyptian patients with chronic kidney disease stage V on regular hemodialysis.
Patients and methods
A total of 70 patients with chronic kidney disease stage V on regular hemodialysis with HCV infection were enrolled in this prospective cohort study, where 37 patients (group A) received OBV/PTV/RTV combination therapy plus ribavirin for 12 weeks. The remaining 33 patients (group B) refused treatment. The sustained virologic response and the adverse events were monitored.
Results
A total of 35 patients of group A [35/37 (94.6%)] completed 12 weeks of HCV therapy, and all of them [35/35 (100%)] achieved sustained virologic response 12. The patients suitably tolerated the therapy. Pruritis (65.7%), anemia (62.9%), gastrointestinal tract manifestations (60%), and fatigue (35%) were the most frequently reported adverse effects. There was a nonsignificant decrease in the hemoglobin and the hematocrit values in the treatment group.
Conclusion
OBV/PTV/RTV combination therapy plus ribavirin can be used safely and effectively in the treatment of chronic HCV-infected patients on regular hemodialysis. The drug combination is safe and tolerable. |
| first_indexed | 2024-04-24T14:34:58Z |
| format | Article |
| id | doaj.art-0ecbcbf83bae4496a999ea7b672e540c |
| institution | Directory Open Access Journal |
| issn | 2537-091X 2537-0928 |
| language | English |
| last_indexed | 2024-04-24T14:34:58Z |
| publishDate | 2021-01-01 |
| publisher | General Organization of Teaching Hospitals and Institutes |
| record_format | Article |
| series | Journal of Medicine in Scientific Research |
| spelling | doaj.art-0ecbcbf83bae4496a999ea7b672e540c2024-04-03T00:38:38ZengGeneral Organization of Teaching Hospitals and InstitutesJournal of Medicine in Scientific Research2537-091X2537-09282021-01-014217017510.4103/jmisr.jmisr_114_20The efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin in hepatitis C virus-infected patients with end-stage renal disease on regular hemodialysisMuhammad M A. GhaffarDalia OmranEnass El SayedBackground and aim Infection with hepatitis C virus (HCV) is an important cause of mortality and morbidity in patients with end-stage renal disease. Direct-acting antiviral drugs allow for the treatment of this group of patients. The current research aims to assess the efficacy and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/RTV) combination therapy plus ribavirin in the treatment of HCV-infected Egyptian patients with chronic kidney disease stage V on regular hemodialysis. Patients and methods A total of 70 patients with chronic kidney disease stage V on regular hemodialysis with HCV infection were enrolled in this prospective cohort study, where 37 patients (group A) received OBV/PTV/RTV combination therapy plus ribavirin for 12 weeks. The remaining 33 patients (group B) refused treatment. The sustained virologic response and the adverse events were monitored. Results A total of 35 patients of group A [35/37 (94.6%)] completed 12 weeks of HCV therapy, and all of them [35/35 (100%)] achieved sustained virologic response 12. The patients suitably tolerated the therapy. Pruritis (65.7%), anemia (62.9%), gastrointestinal tract manifestations (60%), and fatigue (35%) were the most frequently reported adverse effects. There was a nonsignificant decrease in the hemoglobin and the hematocrit values in the treatment group. Conclusion OBV/PTV/RTV combination therapy plus ribavirin can be used safely and effectively in the treatment of chronic HCV-infected patients on regular hemodialysis. The drug combination is safe and tolerable.http://www.jmsr.eg.net/article.asp?issn=2537-091X;year=2021;volume=4;issue=2;spage=170;epage=175;aulast=A.chronic hepatitis c virusdirect-acting antiviral therapyefficacyhemodialysisombitasvir/paritaprevir/ritonavir combination therapysafetysustained virological responsetreatment |
| spellingShingle | Muhammad M A. Ghaffar Dalia Omran Enass El Sayed The efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin in hepatitis C virus-infected patients with end-stage renal disease on regular hemodialysis Journal of Medicine in Scientific Research chronic hepatitis c virus direct-acting antiviral therapy efficacy hemodialysis ombitasvir/paritaprevir/ritonavir combination therapy safety sustained virological response treatment |
| title | The efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin in hepatitis C virus-infected patients with end-stage renal disease on regular hemodialysis |
| title_full | The efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin in hepatitis C virus-infected patients with end-stage renal disease on regular hemodialysis |
| title_fullStr | The efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin in hepatitis C virus-infected patients with end-stage renal disease on regular hemodialysis |
| title_full_unstemmed | The efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin in hepatitis C virus-infected patients with end-stage renal disease on regular hemodialysis |
| title_short | The efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin in hepatitis C virus-infected patients with end-stage renal disease on regular hemodialysis |
| title_sort | efficacy and safety of ombitasvir paritaprevir ritonavir plus ribavirin in hepatitis c virus infected patients with end stage renal disease on regular hemodialysis |
| topic | chronic hepatitis c virus direct-acting antiviral therapy efficacy hemodialysis ombitasvir/paritaprevir/ritonavir combination therapy safety sustained virological response treatment |
| url | http://www.jmsr.eg.net/article.asp?issn=2537-091X;year=2021;volume=4;issue=2;spage=170;epage=175;aulast=A. |
| work_keys_str_mv | AT muhammadmaghaffar theefficacyandsafetyofombitasvirparitaprevirritonavirplusribavirininhepatitiscvirusinfectedpatientswithendstagerenaldiseaseonregularhemodialysis AT daliaomran theefficacyandsafetyofombitasvirparitaprevirritonavirplusribavirininhepatitiscvirusinfectedpatientswithendstagerenaldiseaseonregularhemodialysis AT enasselsayed theefficacyandsafetyofombitasvirparitaprevirritonavirplusribavirininhepatitiscvirusinfectedpatientswithendstagerenaldiseaseonregularhemodialysis AT muhammadmaghaffar efficacyandsafetyofombitasvirparitaprevirritonavirplusribavirininhepatitiscvirusinfectedpatientswithendstagerenaldiseaseonregularhemodialysis AT daliaomran efficacyandsafetyofombitasvirparitaprevirritonavirplusribavirininhepatitiscvirusinfectedpatientswithendstagerenaldiseaseonregularhemodialysis AT enasselsayed efficacyandsafetyofombitasvirparitaprevirritonavirplusribavirininhepatitiscvirusinfectedpatientswithendstagerenaldiseaseonregularhemodialysis |